Legend Biotech (LEGN) has reported Q1 2026 revenue of US$305.1 million, with a basic EPS loss of US$0.29 and a net loss of US$54.3 million, setting the tone for a quarter where top line scale contrasts with continued spending. Over recent periods, revenue has moved from US$186.6 million in Q4 2024 to US$195.1 million in Q1 2025 and then to US$305.1 million in Q1 2026. Basic EPS has shifted from a profit of US$0.14 in Q4 2024 to losses of US$0.55 in Q1 2025 and US$0.29 in Q1 2026, leaving investors focused on how quickly margins can move toward breakeven and beyond.

See our full analysis for Legend Biotech.

With the numbers on the table, the next step is to see how this earnings profile lines up against the widely followed growth, profitability, and valuation narratives around Legend Biotech, and where those stories might need a reset.

Losses on trailing US$250 million still weigh on the story

• On a trailing 12‑month basis, Legend Biotech has generated US$1.1b in revenue while reporting a net loss of about US$250.1 million and a basic EPS loss of US$1.35, so the business is still firmly in investment mode even at this larger scale.
• Consensus narrative points to revenue growth of 27.3% a year and a margin shift from a loss of 28.8% to a profit margin of 23.6%. However, the current trailing 12‑month loss of US$250.1 million and recent quarterly losses between US$30.8 million and US$125.4 million show that the path from investment phase to those profitability assumptions is still a key execution question.
  • Analysts expecting earnings of US$501.1 million by around 2029 are building that view on top of a base where trailing net income is still a loss of US$250.1 million, so you are comparing a future profit pool to today’s sizeable losses.
  • What stands out is that quarterly net losses moved from US$100.9 million in Q1 2025 to US$54.3 million in Q1 2026. This sits between the bullish idea of improving operating leverage and the reality that profitability targets are being projected off a business that has not yet produced consistent profits.

Forecast 51.39% earnings growth versus current Q1 loss

• Forecasts cite earnings growth of 51.39% per year with an expectation of profitability within about three years, while the latest Q1 2026 numbers still show a basic EPS loss of US$0.29 and a net loss of US$54.3 million, compared with quarterly losses ranging from US$30.8 million to US$125.4 million across 2025.
• Bulls argue that rapid CARVYKTI uptake, pipeline breadth, and manufacturing expansion can support that 51.39% earnings growth. Yet the recent pattern of quarterly net losses tests how quickly those bullish expectations can translate into the kind of margin swing analysts are using in their models.
  • The bullish view references long term survival data and expanding indications for CARVYKTI, while the financials still show trailing 12‑month EPS at a loss of US$1.35, which means the transition from data and adoption to bottom line improvement is not yet visible in reported profits.
  • Supporters also point to a pipeline that, at one point in 2025, included 13 Phase I, 4 Phase II, and 3 Phase III products. However, the cash cost of that breadth is embedded in the net loss of US$296.8 million on the trailing 12‑month line at the end of 2025, reminding you that pipeline strength and near term earnings can pull in opposite directions.

Bulls who want to see how those growth and margin assumptions stack up against detailed narrative work can go deeper via the 🐂 Legend Biotech Bull Case

P/S discount and US$122.85 DCF fair value gap

• At a share price of US$28.67, Legend Biotech is trading on a P/S of 4.7x, compared with 9.7x for the US Biotechs industry and 8.2x for peers, and well below the cited DCF fair value of US$122.85, so the market price sits at a large discount to both the sector multiples and that DCF reference point.
• Bears focus on heavy CARVYKTI concentration, high R&D spend, and pricing pressure, and the current P/S discount plus the trailing 12‑month loss of US$250.1 million give that cautious view some numerical backing even as the 17.1% revenue growth forecast and gap to the US$122.85 DCF fair value pull in the opposite direction.
  • Critics highlight that, with trailing 12‑month revenue of US$1.1b and no reported profits, the lower P/S ratio can be seen as the market adjusting for execution and concentration risks rather than simply offering a bargain.
  • At the same time, a forecast revenue growth rate of 17.1% per year that sits above the 11.6% US market reference suggests that the discount is being set against a backdrop of expected growth, which is exactly where bullish and bearish narratives most clearly diverge.

If you are weighing that valuation gap against the risks around CARVYKTI reliance and spending, it helps to see how the cautious narrative frames those same numbers in context 🐻 Legend Biotech Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Legend Biotech on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of optimism and caution feels familiar, move quickly from headline sentiment to your own view by reviewing the company’s 2 key rewards

Explore Alternatives

Legend Biotech combines trailing 12‑month revenue of US$1.1b with ongoing net losses and reliance on CARVYKTI, so profitability and concentration risks remain front of mind.

If you want ideas where balance sheets and earnings profiles aim for more resilience than this loss making story, start your search with the 68 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.